As the Perkins & Will Dallas Director of Healthcare Planning, Julie specializes in market analysis studies and strategic facility plans. She is also Co-Director of the firmwide Resiliency Task Force, finding new ways to breathe sustainability and resiliency into every project while improving patient experience and outcomes. As an expert on resiliency, she worked on the first pilot project for the RELi action item list, Christus Spohn in Corpus Christi, to ensure they remain open and operational throughout a crisis through resilient construction, regional response, and community connection, industrial disaster response and epidemic response. She has also worked on the second pilot project, OUMC in Oklahoma City, which is now under construction and responds to an entirely different climate. Julie’s vast experience has led her to be an expert in her field coupling healthcare and resilient design together.
Derek Ansel is the Vice President, Therapeutic Strategy Lead, Rare Disease at Worldwide Clinical Trials. Mr. Ansel has worked in clinical research for more than a decade with a focus almost exclusively in rare and pediatric diseases, including non-malignant hematology, autoimmune diseases, metabolic disorders, movement disorders, and other genetic conditions. At Worldwide, he leads and supports corporate initiatives within rare and pediatric diseases and maintains relationships with over 60 patient-focused advocacy organizations. He holds a master’s degree in Pharmacology and Toxicology from Michigan State University and is pursuing a master’s degree in Genetic Counseling from Bay Path University.
Ryoma (Ray) Collia is Vice President Sales at S-Clinica. With a solid background in sales for over thirty-three years, with a particular focus on business development and strategic growth, Ryoma brings over ten years of experience in Life Sciences, seven of which has been within Clinical Trials.
Ryoma made a move into the Life Sciences sector to ‘give back’ to the industry after his wife’s life was dramatically saved by doctors and nurses in 2007 and her subsequent recovery 18 months later. Since then, Ryoma has worked closely with Pharma, CROs, Sites and Patient Advocacy groups to achieve that goal.
He is a passionate advocate for patients and clinical sites, and is also very proud to volunteer for and support the Pharmaceutical Contract Management Group as a Steering Committee Member.
